Lung Cancer
Data show Avastin plus chemotherapy improves survival in lung cancer patients
Published in Oncology Business Week, January 14th, 2007
Genentech, Inc. (DNA) announced the publication of data from a pivotal Phase III clinical trial in the New England Journal of Medicine showing that Avastin (bevacizumab) in combination with paclitaxel and carboplatin chemotherapy significantly improved overall survival in patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC).
Based on this study (E4599), the U.S. Food and Drug Administration (FDA) recently approved Avastin as a first-line treatment in combination with paclitaxel and carboplatin chemotherapy for patients with this advanced form of lung cancer.
According to the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- Anemia
Abt analysis suggests lower drug cost for Procrit in outpatient setting - Anemia
Affymax presents results from phase II trial of Hematide in anemic cancer patients - Anemia
Data show efficacy of extended dosing of Aranesp in treatment of chemotherapy-induced anemia - Anemia
Phase II data show promise of Aranesp treatment for anemia of cancer - Anemia
Target hemoglobin achieved in study of epoetin alfa in cancer-related anemic patients - Awards
Breast cancer foundation names 2006 Komen Brinker award winners for scientific distinction - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
